Naturally rewarding stimuli (i.e. food, sex, etc) increase the activity of dopamine cells in the mesocorticolimbic dopamine system causing increased dopamine release in brain areas such as the nucleus ...

The adenosine pathway has emerged as an attractive target for immuno-oncology R&D because it is thought to reduce the activity of misfunctioning regulatory T-cells that inhibit the immune response ...

Exciting results are expected this year, from multiple mid and late stage clinical trials and involving a broad array of adenosine drugs including CD73, CD39 and A2AR! To ensure the community can ...

In intact mouse models, adenosine significantly reduced and DPCPX significantly increased the power of harmaline-induced tremor compared with baseline tremor in the same mouse (P <0.05 for both).

Inozyme Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics that target the PPi-Adenosine Pathway, a key regulator of bone health and blood vessel ...

A live webcast of the fireside chat can be accessed from the Investor Relations section of Inozyme’s website under events, where a replay of the event will also be available for a limited time.